Sichuan Hebang Biotechnology Corporation Limited

Symbol: 603077.SS

SHH

2.39

CNY

Market price today

  • 14.8503

    P/E Ratio

  • 0.6683

    PEG Ratio

  • 20.85B

    MRK Cap

  • 0.02%

    DIV Yield

Sichuan Hebang Biotechnology Corporation Limited (603077-SS) Financial Statements

On the chart you can see the default numbers in dynamics for Sichuan Hebang Biotechnology Corporation Limited (603077.SS). Companys revenue shows the average of 4350.795 M which is 0.220 % gowth. The average gross profit for the whole period is 1353.074 M which is 0.430 %. The average gross profit ratio is 0.282 %. The net income growth for the company last year performance is 0.261 % which equals 99.300 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Sichuan Hebang Biotechnology Corporation Limited, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.345. In the realm of current assets, 603077.SS clocks in at 9718.872 in the reporting currency. A significant portion of these assets, precisely 4591.309, is held in cash and short-term investments. This segment shows a change of 1.597% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 677.368, if any, in the reporting currency. This indicates a difference of 11.943% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 430.022 in the reporting currency. This figure signifies a year_over_year change of 0.325%. Shareholder value, as depicted by the total shareholder equity, is valued at 19118.357 in the reporting currency. The year over year change in this aspect is 0.342%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2786.155, with an inventory valuation of 2076.05, and goodwill valued at 1838.41, if any. The total intangible assets, if present, are valued at 2170.81.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

balance-sheet.row.cash-and-short-term-investments

16824.894591.31767.9845.9
796.6
1337.9
830.7
308.7
568.5
146.2
308.9
1351.8
358.2
111.7
348.1

balance-sheet.row.short-term-investments

-10.62056.9-9.8
206
0
-0.2
-0.2
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

9703.352786.21803.91829.3
1317.2
1047.1
1655.5
969.6
868.3
663.4
1278.8
553.6
336.2
452.3
297.7

balance-sheet.row.inventory

11833.412076912.2633.3
1317.6
1057.5
1063.8
864.2
820.6
901.9
548.5
448.9
228.8
163.3
82.5

balance-sheet.row.other-current-assets

637.25265.4159.49.2
60.5
72
29.3
1466.7
86.9
72.8
-1.7
-0.7
-0.3
-0.1
-1.6

balance-sheet.row.total-current-assets

38998.99718.94643.43317.6
3491.8
3514.6
3579.3
3609.2
2344.3
1784.3
2134.4
2353.8
922.8
727.2
726.6

balance-sheet.row.property-plant-equipment-net

38155.2894838294.97512.9
7164.7
6386.8
5704.6
5332.7
5087.7
4581.1
2275.7
1729.4
1787.2
1943.9
2271.8

balance-sheet.row.goodwill

7353.621838.41904.51904.5
1904.5
1389.5
1522.4
1522.4
1522.4
1263.2
0
0
0
0
0

balance-sheet.row.intangible-assets

8852.412170.81967.21018.4
1087.8
1080.4
1074.2
1032
968.1
882.9
792.5
645.5
649.2
160.3
134.2

balance-sheet.row.goodwill-and-intangible-assets

16206.044009.23871.72922.9
2992.3
2469.9
2596.6
2554.4
2490.5
2146
792.5
645.5
649.2
160.3
134.2

balance-sheet.row.long-term-investments

2645.57677.4605.1655.4
163.2
496.8
628.8
451
259.4
219.9
0
0
0
0
0

balance-sheet.row.tax-assets

245.84110.325.885.9
38.7
39.3
41.9
73.1
58.6
48.7
29
19.6
34
35.5
4.5

balance-sheet.row.other-non-current-assets

463.9103.9481.4245.3
633.4
379.9
557.6
907.4
957.1
352.2
350.8
298.2
288.9
252
30

balance-sheet.row.total-non-current-assets

57716.6314383.813278.911422.4
10992.3
9772.6
9529.5
9318.6
8853.2
7347.9
3448
2692.7
2759.4
2391.7
2440.5

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

96715.5324102.617922.414740
14484.1
13287.2
13108.8
12927.8
11197.4
9132.2
5582.4
5046.4
3682.2
3118.8
3167.1

balance-sheet.row.account-payables

7522.311877.51156.11041.8
971.1
742.9
697.3
670.7
785.5
801.5
264.8
148.5
294.1
282.5
368.7

balance-sheet.row.short-term-debt

5115.761389.71267.81882.8
1630
851.3
421.3
443.3
2709.3
2271.3
1145
663
660.5
690
861.9

balance-sheet.row.tax-payables

384.3138223.353.4
38.4
44.8
46.1
38.4
50.6
23.1
-3.1
-1.4
75.1
-0.9
-67.3

balance-sheet.row.long-term-debt-total

1730430105.2262.4
226
308
494.3
795.8
863.8
1001.8
805
745
1223
1000
1125

Deferred Revenue Non Current

314.77916.815.9
17.1
18.4
19.7
22.4
27.7
23.6
-805
-745
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

411.69---
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

397.9233.438.411.4
74.8
121.4
79.2
103.8
102.9
55.5
34.6
67.9
69.3
43.3
53.3

balance-sheet.row.total-non-current-liabilities

2456.39605.1161.9280.6
246.1
328
515.7
820.6
894.3
1029.2
805.7
745.7
1223
1000
1134.9

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

73.921.537.122.7
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

16326.84339.43285.13432.6
3031.1
2088.4
1833.9
2151.8
4615.1
4380.1
2292.3
1641.7
2341.3
2144.2
2429.5

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

353258831.38831.38831.3
8831.3
8831.3
8831.3
4014.2
3312.2
1011.1
450
450
350
350
300

balance-sheet.row.retained-earnings

36546.058824.85292.72393.5
2390.6
1886
1702
2047.5
1783.2
1620.5
968.9
1089.1
741.8
410.1
293.8

balance-sheet.row.accumulated-other-comprehensive-income-loss

5899.321281.6608.1224.3
89.7
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

61.38180.7-486.6-307.2
-78
255.1
454.4
4395.1
1192.4
2120.5
1871.2
1865.6
249.1
214.5
54.3

balance-sheet.row.total-stockholders-equity

77831.7519118.414245.411141.8
11233.5
10972.3
10987.6
10456.8
6287.9
4752.1
3290.2
3404.7
1340.9
974.6
648.1

balance-sheet.row.total-liabilities-and-stockholders-equity

96715.5324102.617922.414740
14484.1
13287.2
13108.8
12927.8
11197.4
9132.2
5582.4
5046.4
3682.2
3118.8
3167.1

balance-sheet.row.minority-interest

2556.98644.9391.8165.7
219.5
226.5
287.3
319.2
294.5
0
0
0
0
0
89.6

balance-sheet.row.total-equity

80388.7319763.214637.311307.5
11453
11198.8
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

96715.53---
-
-
-
-
-
-
-
-
-
-
-

Total Investments

2634.95677.4662645.6
369.2
496.8
628.7
450.8
259.4
219.9
350.8
298.2
288.9
252
30

balance-sheet.row.total-debt

6845.771819.71372.92145.2
1856
1159.3
915.5
1239.1
3573
3273.1
1950
1408
1883.5
1690
1986.9

balance-sheet.row.net-debt

-9979.12-2771.6-338.11299.3
1265.5
-178.7
84.8
930.4
3004.5
3126.9
1641.1
56.2
1525.3
1578.3
1638.8

Cash Flow Statement

The financial landscape of Sichuan Hebang Biotechnology Corporation Limited has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.169. The company recently extended its share capital by issuing 668.69, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -807242334.320 in the reporting currency. This is a shift of -0.531 from the previous year. In the same period, the company recorded 929.6, 62.65, and -1291, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -197.83 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 2493.81, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

cash-flows.row.net-income

1398.353810.23031.32.9
506.6
298.2
505.2
321.5
238.7
671.8
64.4
334.9
366.3
170.7
43.2

cash-flows.row.depreciation-and-amortization

238.89929.6643.9643
635.6
575.1
525.5
417.6
322.8
268.7
197.3
195.2
202.1
153.7
72.8

cash-flows.row.deferred-income-tax

1777.51-28.497.6-47.9
1.7
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

506.49506.5-97.647.9
-1.7
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-2261.66-2177.8-543.5-364.2
-1064.3
-160.3
-903.8
-173.2
-214.3
-292.7
-727.9
-481.7
-130.6
-65.5
-66.7

cash-flows.row.account-receivables

-1083.06-1083.129.8-468.3
-305.9
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-1178.6-1178.6-278.9678.3
-269.2
6.3
-193.7
17.3
125.9
-353.4
-99.5
-220.2
-65.5
-80.8
-9.6

cash-flows.row.account-payables

0112.3-313.4-526.3
-490.8
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-28.419-47.9
1.7
-166.5
-710.1
-190.6
-340.2
60.7
-628.3
-261.5
-65.1
15.3
-57.1

cash-flows.row.other-non-cash-items

-1083.44-395.96587.2
85
231.3
50
9.4
102
-443.1
58.6
86.5
114.7
71.8
19.7

cash-flows.row.net-cash-provided-by-operating-activities

576.13000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-613.5-936.2-1735.1-197.1
-662.5
-363.6
-508.5
-677.4
-1130.5
-716.8
-598.5
-273.8
-345.2
-571
-848.5

cash-flows.row.acquisitions-net

-66.1417.9-2.4
-643.9
0.2
2.2
15.8
-189.1
15.1
-255.9
0
345.2
93
0

cash-flows.row.purchases-of-investments

-81.670-57.5-352.2
-332.8
-86.2
-180.3
-1638.8
-120
0
-1050
0
-31.4
-213.6
-20

cash-flows.row.sales-maturities-of-investments

123.762.351.8336.5
280.5
132.4
1486.8
109.9
247.9
27.5
1005.6
30.3
0.4
60.7
0

cash-flows.row.other-investing-activites

0.5562.70.34.7
82.4
-3.2
-4.7
8.7
-62
62
0
0
-345.2
0
0

cash-flows.row.net-cash-used-for-investing-activites

-637.01-807.2-1722.5-210.4
-1276.4
-320.3
795.4
-2181.8
-1253.7
-612.2
-898.9
-243.5
-376.1
-630.9
-868.5

cash-flows.row.debt-repayment

-1595-1291-2078-1634.8
-1064.9
-1926.8
-2264.4
-4342.1
-3833
-1763
-708
-900.5
-782
-926.9
-839.8

cash-flows.row.common-stock-issued

668.69668.7179.9120.1
250
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

-668.69-668.7-179.9-120.1
-250
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-462.71-197.8-78-92.7
-71.1
-253.2
-110.2
-198.4
-378.7
-215
-273.8
-123.3
-121.3
-126.1
-147.2

cash-flows.row.other-financing-activites

1828.992493.81536.61806
1503.1
2020
1927.3
5873.8
5438.4
2239.6
1221.2
2126.1
973.6
1120.8
1802

cash-flows.row.net-cash-used-provided-by-financing-activities

-228.721005-619.478.4
367.1
-160
-447.4
1333.3
1226.6
261.7
239.4
1102.3
70.4
67.8
814.9

cash-flows.row.effect-of-forex-changes-on-cash

5.2921.9-10.626.2
9.3
36.1
-23.2
13.4
6.9
0.5
-0.1
0
-0.4
-0.2
0

cash-flows.row.net-change-in-cash

25.352863.9844.3263.1
-737.1
500.1
501.8
-259.8
429.1
-145.4
-1067
993.7
246.5
-232.6
15.4

cash-flows.row.cash-at-end-of-period

16431.524544.91681836.7
573.5
1310.6
810.5
308.7
568.5
139.5
284.8
1351.8
358.2
111.7
344.3

cash-flows.row.cash-at-beginning-of-period

16406.161681836.7573.5
1310.6
810.5
308.7
568.5
139.5
284.8
1351.8
358.2
111.7
344.3
328.9

cash-flows.row.operating-cash-flow

576.132644.33196.7368.9
162.9
944.4
176.9
575.3
449.2
204.7
-407.5
135
552.6
330.8
69

cash-flows.row.capital-expenditure

-613.5-936.2-1735.1-197.1
-662.5
-363.6
-508.5
-677.4
-1130.5
-716.8
-598.5
-273.8
-345.2
-571
-848.5

cash-flows.row.free-cash-flow

-37.361708.11461.7171.8
-499.6
580.8
-331.6
-102.2
-681.3
-512.1
-1006
-138.9
207.4
-240.2
-779.6

Income Statement Row

Sichuan Hebang Biotechnology Corporation Limited's revenue saw a change of 0.321% compared with the previous period. The gross profit of 603077.SS is reported to be 5587.63. The company's operating expenses are 1047.7, showing a change of 115.525% from the last year. The expenses for depreciation and amortization are 929.6, which is a 0.464% change from the last accounting period. Operating expenses are reported to be 1047.7, which shows a 115.525% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.246% year-over-year growth. The operating income is 4481.16, which shows a 0.246% change when compared to the previous year. The change in the net income is 0.261%. The net income for the last year was 3806.81.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

income-statement-row.row.total-revenue

8980.0913038.99867.15260.8
5969.1
6009
4737.6
3462.6
2862.6
2185.7
1602.7
1737.8
1900
1432.9
844.4

income-statement-row.row.cost-of-revenue

6637.587451.35729.64272
4609.2
4680.8
3534.9
2636.2
2234.9
1727.4
1295.5
1085.2
1092.6
973.4
645.1

income-statement-row.row.gross-profit

2342.55587.64137.5988.8
1359.9
1328.2
1202.8
826.4
627.8
458.3
307.2
652.6
807.4
459.4
199.2

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

72.13---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

-280.71---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

56.12---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

789.52853.8335.1272.4
301.1
1.7
0.3
30.7
63.5
0.7
0.2
5.6
0
7.4
2.2

income-statement-row.row.operating-expenses

657.681047.7486.1457.9
688.7
686.5
556.8
473
303.3
223.1
189.1
183
207.7
195.8
133

income-statement-row.row.cost-and-expenses

7295.2684996215.84729.9
5297.9
5367.3
4091.7
3109.2
2538.2
1950.5
1484.6
1268.2
1300.4
1169.2
778.2

income-statement-row.row.interest-income

-5.8122.79.43.7
6.9
6.8
7.3
4.3
1.4
1
11.5
11.5
0.6
1.1
5.3

income-statement-row.row.interest-expense

47.5551.477.882.2
57
58.3
61.9
112.7
120.3
133.8
82.3
118.8
129.7
80.5
23.6

income-statement-row.row.selling-and-marketing-expenses

56.12---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-0.88-2.6-12.7-76.2
1.1
-226
-49.9
16.2
-42.2
444.2
-47.6
-79.8
-114.7
-64.5
-17.5

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

789.52853.8335.1272.4
301.1
1.7
0.3
30.7
63.5
0.7
0.2
5.6
0
7.4
2.2

income-statement-row.row.total-operating-expenses

-0.88-2.6-12.7-76.2
1.1
-226
-49.9
16.2
-42.2
444.2
-47.6
-79.8
-114.7
-64.5
-17.5

income-statement-row.row.interest-expense

47.5551.477.882.2
57
58.3
61.9
112.7
120.3
133.8
82.3
118.8
129.7
80.5
23.6

income-statement-row.row.depreciation-and-amortization

140.811034.9707643
716.7
575.1
525.5
417.6
322.8
268.7
197.3
195.2
202.1
153.7
72.8

income-statement-row.row.ebitda-caps

1791.07---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

1650.274481.23595.992
582.7
414
595.8
339
218.7
678.7
70.3
384.2
485
192.9
46.5

income-statement-row.row.income-before-tax

1649.394478.63583.215.8
583.8
415.7
596.1
369.6
282.3
679.4
70.5
389.8
485
199.1
48.8

income-statement-row.row.income-tax-expense

259.44668.3551.912.9
77.1
117.5
90.9
48.1
43.5
7.7
6.1
54.9
118.7
28.4
5.5

income-statement-row.row.net-income

1398.353806.83018.52.9
516.9
363.1
517.5
317.8
239.9
671.8
64.4
334.9
366.3
172.8
44.2

Frequently Asked Question

What is Sichuan Hebang Biotechnology Corporation Limited (603077.SS) total assets?

Sichuan Hebang Biotechnology Corporation Limited (603077.SS) total assets is 24102627180.000.

What is enterprise annual revenue?

The annual revenue is 4039994103.000.

What is firm profit margin?

Firm profit margin is 0.261.

What is company free cash flow?

The free cash flow is -0.004.

What is enterprise net profit margin?

The net profit margin is 0.156.

What is firm total revenue?

The total revenue is 0.184.

What is Sichuan Hebang Biotechnology Corporation Limited (603077.SS) net profit (net income)?

The net profit (net income) is 3806808869.000.

What is firm total debt?

The total debt is 1819709253.000.

What is operating expences number?

The operating expences are 1047699198.000.

What is company cash figure?

Enretprise cash is 3882595407.000.